Small molecules against the origin and activation of myofibroblast for renal interstitial fibrosis therapy

• Main Authors: Ya-long Feng, Wen-bo Wang, Yue Ning, Hua Chen, Pei Liu
• Format: Article
• Language: English
• Published: Elsevier 2021-07-01
• Series: Biomedicine & Pharmacotherapy
• Subjects: Renal interstitial fibrosis; Chronic kidney diseases; Small molecule; Natural product; Myofibroblast
• Online Access: http://www.sciencedirect.com/science/article/pii/S0753332221001712

Renal interstitial fibrosis (RIF) is a common pathological response in a broad range of prevalent chronic kidney diseases and ultimately leads to renal failure and death. Although RIF causes a high morbi-mortality worldwide, effective therapeutic drugs are urgently needed. Myofibroblasts are identified as the main effector during the process of RIF. Multiple types of cells, including fibroblasts, epithelial cells, endothelial cells, macrophages and pericytes, contribute to renal myofibroblasts origin, and lots of mediators, including signaling pathways (Transforming growth factor-β1, mammalian target of rapamycin and reactive oxygen species) and epigenetic modifications (Histone acetylation, microRNA and long non-coding RNA) are participated in renal myofibroblasts activation during renal fibrogenesis, suggesting that these mediators may be the promising targets for treating RIF. In addition, many small molecules show profound therapeutic effects on RIF by suppressing the origin and activation of renal myofibroblasts. Taken together, the review focuses on the mechanisms of the origin and activation of renal myofibroblasts in RIF and the small molecules against them improving RIF, which will provide a new insight for RIF therapy.